SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer [Rapid Communication]

Conclusion
The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant or liver-only metastatic colorectal cancer did not improve PFS at any site but significantly delayed disease progression in the liver. The safety profile was as expected and was consistent with previous studies.

Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: van Hazel, Heinemann, Sharma, Findlay, Ricke, Peeters, Perez, Robinson, Strickland, Ferguson, Rodriguez, Kroning, Wolf, Ganju, Walpole, Boucher, Tichler, Shacham-Shmueli, Powell, Eliadis, Isaacs, Price, Moeslein, Taieb, Bower, Gebski, Van Buskirk, Cade, T Tags: Clinical Trials, Radiation, Chemotherapy, Combined Modality, Radiation, Chemotherapy, Combined Modality, Radiation Oncology, Rapid Communications, Interventional Radiology Source Type: research